2010-11-10 00:00:00,Forest Announces Executive Management Promotions And Retirement Of Lawrence Olanoff As President And Chief Operating Officer
2011-01-18 00:00:00,Forest Raises FY 2011 EPS Guidance
2011-01-20 00:00:00,Forest And Pierre Fabre Medicament Announce Topline Phase III Results From A Study Of Levomilnacipran For The Treatment Of Major Depressive Disorder
2011-02-28 00:00:00,Kendall Law Group Investigates Forest For Shareholders
2011-03-08 00:00:00,Forest Commences Tender Offer For All Outstanding Shares And Certain Notes And Warrants Of Clinical
2011-04-04 00:00:00,Forest Magnolia Acquisition Announces Amendment To Merger Agreement And Extends Tender Offer To Acquire Clinical
2011-04-19 00:00:00,Forest Subsidiary And Blue Ash Therapeutics Enter Into Asset Purchase Agreement For a Phase III Antiarrhythmic Agent
2011-06-03 00:00:00,Forest Announces Accelerated Share Repurchase
2011-07-19 00:00:00,Forest Reaffirms FY FY 2013 EPS Call
2011-08-09 00:00:00,Ironwood Pharmaceuticals Inc And Forest Announce Submission Of New Drug Application For Linaclotide For Treatment Of Irritable Bowel Syndrome
2011-08-15 00:00:00,Forest Announces Additional Accelerated Share Repurchase
2011-10-24 00:00:00,Ironwood And Forest Announce Linaclotide New Drug Application For Treatment Of Irritable Bowel Syndrome With Constipation And Chronic Constipation Accepted For FDA Review
2012-01-17 00:00:00,Forest Raises FY 2012 EPS Guidance
2012-02-24 00:00:00,Forest And Almirall SA Announce Positive FDA Advisory Committees Recommendation For Approval of Aclidinium Bromide For The Treatment Of Chronic Obstructive Pulmonary Disease
2012-02-28 00:00:00,Forest And Gedeon Richter Announce Results From Two Positive Phase III Trials With Investigational Antipsychotic Cariprazine For Treatment Of Schizophrenia
2012-03-07 00:00:00,Forest And Pierre Fabre Medicament Announces Positive Phase III Results For Levomilnacipran In Patients With Depressive Disorder
2012-04-17 00:00:00,Forest Issues FY 2013 EPS Guidance Below Estimates
2012-04-26 00:00:00,Forest Laboratories Inc And Pierre Fabre Medicament Announce Third Positive Phase III Study For Levomilnacipran In Patients With Depressive Disorder
2012-08-30 00:00:00,Ironwood Pharmaceuticals Inc And Forest Laboratories Inc Announce Approval Of LINZESS For Treatment Of Irritable Bowel Syndrome With Constipation And Chronic Idiopathic Constipation
2012-10-11 00:00:00,Forbes Earnings Forest Laboratories
2012-10-18 00:00:00,Ironwood Pharma Beats on All Fronts Analyst Blog
2012-10-25 00:00:00,Zacks Gives Neutral Rating to Forest Laboratories
2012-11-01 00:00:00,Financial Review on Healthcare Stocks Forest Laboratories and Endo
2012-11-05 00:00:00,FOREST Six New Plaintiffs Join Sanford
2012-11-06 00:00:00,Is Pharma Stock Forest Laboratories a Hold or
